AutoImmune Inc. Reports 2008 Second Quarter Financial Results PASADENA, Calif., Aug.7 /PRNewswire-FirstCall/ -- AutoImmune Inc.
today reported a net loss of $86,000, or $0.01 per share basic and diluted, for the three months ended June 30, 2008, compared with a net loss of $62,000, or break...
AutoImmune Inc. Reports 2008 Second Quarter Financial Results PASADENA, Calif., Aug.7 /PRNewswire-FirstCall/ -- AutoImmune Inc.
today reported a net loss of $86,000, or $0.01 per share basic and diluted, for the three months ended June 30, 2008, compared with a net loss of $62,000, or break...
Encephalomyelitis Therapy: New findings from T.K. Makar and co-authors in the area of encephalomyelitis therap New findings from T.K.Makar and co-authors in the area of encephalomyelitis therapy published (NewsRx.com) -- New research, 'Stem cell based delivery of IFN-beta reduces relapses in experimental autoimmune encephalomyelitis,' is the...
Idera Pharmaceuticals Reports Second Quarter 2008 Financial Results - Idera Pharmaceuticals, Inc.(Nasdaq: IDRA), a biopharmaceutical company focused on developing therapeutics targeting Toll-Like Receptors (TLR), today reported financial results for the second quarter and six months ended June 30, 2008.
Idera Pharmaceuticals Reports Second Quarter 2008 Financial Results IMO-3100 Selected as Lead Toll-Like Receptor Antagonist Candidate in Autoimmune Disease Indications CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc.(Nasdaq: IDRA - News), a biopharmaceutical company focused on...
Idera Pharmaceuticals Reports Second Quarter 2008 Financial Results IMO-3100 Selected as Lead Toll-Like Receptor Antagonist Candidate in Autoimmune Disease Indications CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc.(Nasdaq: IDRA), a biopharmaceutical company focused on developing...
Idera Pharmaceuticals Reports Second Quarter 2008 Financial Results IMO-3100 Selected as Lead Toll-Like Receptor Antagonist Candidate in Autoimmune Disease Indications CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc.(Nasdaq: IDRA), a biopharmaceutical company focused on developing...
Idera Pharmaceuticals Reports Second Quarter 2008 Financial Results , 7:00 AM EST News source: Business Wire Idera Pharmaceuticals, Inc.(Nasdaq: IDRA), a biopharmaceutical company focused on developing therapeutics targeting Toll-Like Receptors (TLR), today reported financial results for the second...
Idera Pharmaceuticals Reports Second Quarter 2008 Financial Results Idera Pharmaceuticals, Inc.(IDRA), a biopharmaceutical company focused on developing therapeutics targeting Toll-Like Receptors (TLR), today reported financial results for the second quarter and six months ended June 30, 2008.
"We...
Idera Pharmaceuticals Reports Second Quarter 2008 Financial Results Idera Pharmaceuticals, Inc.(Nasdaq: IDRA), a biopharmaceutical company focused on developing therapeutics targeting Toll-Like Receptors (TLR), today reported financial results for the second quarter and six months ended June 30, 2008.
...
Idera Pharmaceuticals Reports Second Quarter 2008 Financial Results CAMBRIDGE, Mass.- (Business Wire) Idera Pharmaceuticals, Inc.
(Nasdaq: IDRA), a biopharmaceutical company focused on developing therapeutics targeting Toll-Like Receptors (TLR), today reported financial results for the second quarter...
Idera Pharmaceuticals Reports Second Quarter 2008 Financial Results CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc.(Nasdaq: IDRA - News), a biopharmaceutical company focused on developing therapeutics targeting Toll-Like Receptors (TLR), today reported financial results for the second...
Idera Pharmaceuticals Reports Second Quarter 2008 Financial Results CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Idera Pharmaceuticals, Inc.(Nasdaq: IDRA), a biopharmaceutical company focused on developing therapeutics targeting Toll-Like Receptors (TLR), today reported financial results for the second quarter and...
Arthritis Immunology: Findings from Medical University of Innsbruck, Department of Pediatrics broaden understa Findings from Medical University of Innsbruck, Department of Pediatrics broaden understanding of arthritis immunology (NewsRx.com) -- Research findings, 'Premature aging of the immune system in children with juvenile idiopathic arthritis,'...
Seattle Genetics Starts Clinical Trial of SGN-70 For Autoimmune Disease Biotech, Antibodies, Seattle Genetics Luke Timmerman 7/31/08 Seattle Genetics, the Bothell, WA-based developer of targeted antibody drugs, said today it has started an early-stage clinical trial to look at safety of SGN-70 in 60 healthy...
Cyclosporine Therapy in Veterinary Dermatology Treating canine and feline dermatoses with cyclosporine has been the subject of great interest in recent years.1 Many studies have focused on canine atopic dermatitis, and now there is substantial evidence that cyclosporine is efficacious in...
The Jackson Laboratory University of California, Davis (UCD)JAX West, a campus-based center that produces genetically customized mice for disease researchers at UC Davis and throughout the Pacific Rim.The center complements the UC Davis Mouse Biology Program.
Pre-Eclampsia May Be an Autoimmune Disorder _ Pre-Eclampsia May Be an Autoimmune Disorder.
Pre-Eclampsia May Be an Autoimmune Disorder _ Pre-Eclampsia May Be an Autoimmune Disorder.
Pre-Eclampsia May Be Autoimmune Disease HOUSTON, July 28 -- In mice, pre-eclampsia looks like an autoimmune disease, a finding that has far-reaching implications for screening, diagnosis, and treatment, researchers said here.Among other things, the auto-antibodies that appear...
Pre-eclampsia May Be Autoimmune Disease Biochemists at The University of Texas Medical School at Houston say they are the first to provide pre-clinical evidence that pregnancy-induced high blood pressure or pre-eclampsia may be an autoimmune disease.Their research could provide...
Pre-eclampsia May Be Autoimmune Disease AUTOIMMUNE DISEASE, PREECLAMPSIA, PRE-ECLAMPSIA Contact Information Available for logged-in reporters only Description Biochemists at The University of Texas Medical School at Houston say they are the first to provide pre-clinical...
Pre-eclampsia May Be Autoimmune Disease Scientists in the laboratory of Yang Xia, M.D., Ph.D., an assistant professor of biochemistry and molecular biology at the UT Medical School at Houston, provided evidence of the connection by inducing symptoms similar to pre-eclampsia in...
New type 1 diabetes immunology study results reported from University of Cambridge, Cambridge Institute for Me (NewsRx.com) -- New investigation results, 'Commonality in the genetic control of Type 1 diabetes in humans and NOD mice: variants of genes in the IL-2 pathway are associated with autoimmune diabetes in both species,' are detailed in a study...
Scientists at Johns Hopkins University, Department of Pathology target pathology (NewsRx.com) -- A report, 'Autoimmune hypophysitis of SJL mice: clinical insights from a new animal model,' is newly published data in Endocrinology.According to recent research from the United States, 'Autoimmune hypophysitis (AH) is a...
